iBio, Inc. (NYSE:IBIO – Get Free Report) traded up 2.5% during mid-day trading on Wednesday . The company traded as high as $2.44 and last traded at $2.42. 57,343 shares traded hands during trading, a decline of 95% from the average session volume of 1,064,661 shares. The stock had previously closed at $2.36.
iBio Stock Performance
The firm’s 50 day moving average is $2.58 and its 200 day moving average is $2.27. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.37 and a current ratio of 3.37.
iBio (NYSE:IBIO – Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.46) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.46). Research analysts anticipate that iBio, Inc. will post -1.74 EPS for the current fiscal year.
iBio Company Profile
iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.
Further Reading
- Five stocks we like better than iBio
- What is a buyback in stocks? A comprehensive guide for investors
- Hedge Funds Boost Oil Positions: Is a Major Rally on the Horizon?
- Ride Out The Recession With These Dividend Kings
- Power Play: Japan’s Top Auto Stocks Eye Historic Merger
- Breakout Stocks: What They Are and How to Identify Them
- S&P 500 Earnings Set to Shine: January’s Critical Market Test
Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.
